Stocks · News reference
Xenetic Biosciences announced that its research on DNase I as a potential strategy to overcome CAR T-cell resistance has been selected for an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today
Filed: 2026-09-23 AccNo: 0001683168-26-007340 Size: 6 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
U.S. stocks mixed: Dow slipped 0.1%, Nasdaq rose 0.7%, S&P 0.3%; tech led gains, energy fell, while oil dropped 3.2%.
Xenetic Biosciences plans to acquire Santersus in an all-stock deal, forming Santersus Bio to tackle NET-driven diseases.
U.S. stocks edged higher as strong retail sales lifted sentiment; utilities gained, energy fell, oil dropped, while European and Asian markets advanced.